Dandelion Root

Root extract inducing mito collapse/autophagy, inhibiting PI3K/angio; selective preclinical anticancer with limited human data.

← All agents

Human-reviewed · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

🔬⭐⭐ Preclinical — Strong in vitro and animal data; human trials are limited but approved, with recruitment challenges.Taraxacum officinale rootDRE (Dandelion Root Extract)

Forms: Dandelion root powder/capsules (500–2000 mg) · Dandelion root tea/extract

Educational only, not medical advice. OncoForge makes no claim that Dandelion Root treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Simple Summary

In lab models, DRE collapses tumor mitochondrial potential, triggers autophagy-linked death, and tones down PI3K/VEGF signaling. Human oncology data are limited; treat as an adjunct under supervision.

Evidence at a glance

Tier 2 · animalVarious (preclinical models)

Preclinical strong; human limited/ongoing.

How it may work

Dandelion root extract (DRE) induces mitochondrial depolarization, disrupting membrane potential and releasing cytochrome c, leading to caspase-mediated apoptosis. It upregulates Beclin-1 and LC3-II to promote autophagic cell death. DRE inhibits PI3K/Akt signaling, reducing proliferation, and downregulates VEGF to suppress angiogenesis. Preclinical studies show selective toxicity to cancer cells, sparing healthy cells.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

Mitochondrial Depolarization↑Cytochrome c release; apoptosis
Autophagy↑Beclin-1/LC3-II upregulation
PI3K/Akt↓Reduces proliferation
Angiogenesis↓VEGF downregulation
Apoptosis↑Caspase-mediated; selective to cancer cells

Mito CollapseAutophagyPI3KAngio

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Curcumin: Autophagy/apoptosis co-boost.
Berberine: PI3K/Akt co-inhibition.
Chemotherapy: Potential sensitization.

Overlapping mechanisms

Autophagy ↑: Avoid stacking with other strong autophagy inducers without rationale.

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories

Gi Upset MildAllergic ReactionsDiuretic EffectPregnancy Avoid

Potential interactions

Diuretics / LithiumMonitorModerateTheoreticalAdditive diuresis; lithium toxicity risk.
AntidiabeticsMonitorMinorTheoreticalPossible hypoglycemia.
ChemotherapyConsiderBeneficialTheoreticalPotential sensitization; preclinical.

Timing

Anytime: Tea form soothing; powder with meals.
Divided doses: For tolerance.

References

Research

No published studies for Dandelion Root yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of Dandelion Root depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 500–2000 mg (po) Once or divided daily. No established oncology dose; traditional use 1–2 g/day root powder. Preclinical HED from mouse studies (500 mg/kg extract → ~40 mg/kg, ~2.4 g for 60 kg human)., No Rx required. Standardize if possible; tea form milder. Oncology adjunct experimental—consult clinician; monitor for diuresis..

Trials studying Dandelion Root

No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar